Vicapsys Life Sciences, Inc. (VICP)

OTCMKTS · Delayed Price · Currency is USD
1.500
0.00 (0.00%)
At close: Dec 3, 2025
-0.66%
Market Cap 48.56M
Revenue (ttm) n/a
Net Income (ttm) -1.35M
Shares Out 32.37M
EPS (ttm) -0.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 824
Average Volume 657
Open 1.500
Previous Close 1.500
Day's Range 1.500 - 1.500
52-Week Range 0.000 - 3.000
Beta 453,881.05
RSI 46.04
Earnings Date Apr 16, 2026

About Vicapsys Life Sciences

Vicapsys Life Sciences, Inc. focuses on the development and commercialization of VICAPSYN, a proprietary product. The company’s product is applied to transplantation therapies and related stem-cell applications in the transplantation field. It also develops VYBRIN, a product based on CXCL12 for prevention of post-surgical adhesions in abdominal surgery, coating of implantable medical devices and other implants to eliminate fibrosis, and wound healing with a focus on diabetic ulcers. The company was formerly known as Phage Therapeutics Internati... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol VICP
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.